

Columbus Regional Anti-Emetic Guidelines for Chemotherapy

Emetic Category	Chemotherapy Agents			Acute Emesis (highest therapeutic index)	Delayed Emesis
High Risk	<ul style="list-style-type: none"> · AC combination defined as either doxorubicin or epirubicin with cyclophosphamide · Altretamine · Carmustine > 250 mg/m² · Cisplatin ≥ 50 mg/m² · Cyclophosphamide > 1,500 mg/m² · Dacarbazine · Mechlorethamine · Procarbazine (oral) · Streptozocin 			<p>Pretreatment with a 5HT-3 antagonist and a NK1 receptor antagonist and a corticosteroid: ondansetron 12 mg IV (max 32 mg/day) plus aprepitant (Emend®) 125 mg PO plus dexamethasone 10-20 mg IV</p>	<p>Oral Corticosteroid plus a NK1 antagonist (or plus an oral 5HT-3 or metoclopramide): dexamethasone 8 mg PO for 3-4 days, plus aprepitant (Emend®) 80 mg PO for 2 days +/- ondansetron 8 mg PO TID (max 32 mg/day) for 2-3 days or metoclopramide 30-40 mg PO BID-QID for 2-4 days</p>
Moderate Risk	<ul style="list-style-type: none"> · Aldesleukin > 12-15 million units/m² · Amifostine > 300mg/m² · Arsenic trioxide · Azacitidine · Busulfan > 4mg/d · Carboplatin · Carmustine ≤ 250mg/m² · Cisplatin < 50 mg/m² · Cyclophosphamide ≤ 1,500 mg/m² 	<ul style="list-style-type: none"> · Cyclophosphamide (oral) · Cytarabine > 1 g/m² · Dactinomycin · Daunorubicin · Doxorubicin · Epirubicin · Etoposide · Melphalan > 50 mg/m² · Imatinib (oral) · Irinotecan 	<ul style="list-style-type: none"> · Etoposide (oral) · Idarubicin · Ifosfamide · Oxaliplatin > 75 mg/m² · Temozolomide (oral) · Vinorelbine (oral) · Methotrexate 250 - > 1,000 mg/m² · Lomustine 	<p>Pretreatment with a 5HT-3 antagonist and corticosteroid: ondansetron 12 mg IV (max 32 mg/day) plus dexamethasone 10-20 mg IV</p>	<p>Oral Corticosteroid plus an oral 5HT-3 antagonist (or oral metoclopramide) dexamethasone 8 mg PO for 3-4 days, plus ondansetron 8 mg PO TID (max 32 mg/day) for 2-3 days or metoclopramide 30-40 mg PO BID-QID for 2-4 days</p>
Low Risk	<ul style="list-style-type: none"> · Amifostine ≤ 300mg/m² · Bexarotene · Capecitabine · Cetuximab · Cytarabine (low dose) · Docetaxel · Etoposide 	<ul style="list-style-type: none"> · 5-Fluorouracil · Gemcitabine · Methotrexate · Mitomycin · Doxorubicin (liposomal) 	<ul style="list-style-type: none"> · Mitoxantrone · Paclitaxel · Paclitaxel-albumin · Pemetrexed · Topotecan · Fludarabine 	<p>Pretreatment with a corticosteroid: dexamethasone 4 – 8 mg PO</p>	<p>No routine use of anti-emetics recommended</p>
Minimal Risk	<ul style="list-style-type: none"> · Alemtuzumab · Alpha Interferon · Asparaginase · Bevacizumab · Bleomycin · Bortezomib · Dextrazoxane · Erlotinib · Fludarabine · Gefitinib · Gemtuzumab · Hydroxyurea 	<ul style="list-style-type: none"> · Busulfan · Chlorambucil (oral) · Cladribine · Decitabine · Lenalidomide · Melphalan (oral low-dose) · Methotrexate ≤ 50 mg/m² · Nelarabine · Pentostatin 	<ul style="list-style-type: none"> · Denileukin diftitox · Dasatinib · Rituximab · Sorafenib · Sunitinib · Thalidomide · Thioguanine (oral) · Trastuzumab · Valrubicin · Vinblastine · Vincristine · Vinorelbine 	<p>No routine use of anti-emetics recommended</p>	<p>No routine use of anti-emetics recommended</p>

†For combination chemotherapy the patient should be administered the anti-emetics appropriate for the chemotherapeutic agent of greatest emetic risk.